NCT04248153View on ClinicalTrials.gov

Optimal Timing of BR55 CEUS of the Ovaries

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 14, 2019

Primary Completion Date

February 19, 2020

Study Completion Date

July 31, 2021

Conditions
Ovarian Cancer
Interventions
DRUG

BR55

BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg

Trial Locations (1)

94304

Stanford University Medical Center, Palo Alto

Sponsors
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Bracco Diagnostics, Inc

INDUSTRY